Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
36 hedge funds and large institutions have $45.1M invested in Ocera Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1,800% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 1
100% more funds holding
Funds holding: 18 → 36 (+18)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
1% more capital invested
Capital invested by funds: $44.6M → $45.1M (+$503K)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.76M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.29M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.52M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.11M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$829K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.09M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.91M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$413K |
| 4 |
QF
QVT Financial
New York
|
-$239K |
| 5 |
Morgan Stanley
New York
|
-$153K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| $150K | +$203K | +14,205 | New |
|
|
GT
27
Glenmede Trust
Philadelphia,
Pennsylvania
| $119K | +$162K | +11,352 | New |
|
|
CAM
28
ClariVest Asset Management
San Diego,
California
| $67K | +$90.5K | +6,328 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $53K | +$70.9K | +4,960 | +12,400% |
|
30
Wells Fargo
San Francisco,
California
| $47K | +$63.3K | +4,429 | New |
|
|
31
Morgan Stanley
New York
| $12K | -$153K | -10,727 | -90% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $12K | +$7.62K | +533 | +88% |
|
|
AIG
33
American International Group
New York
| $10.6K | +$14.3K | +1,000 | New |
|
|
34
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $10K | -$413K | -28,887 | -97% |
|
|
LTFS
35
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | +$2.15K | +150 | New |
|
36
Barclays
London,
United Kingdom
| – | -$1K | -84 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$29 | +2 | New |
|
OCRX Hedge Fund Activity: Q1 2014 in Review
36 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q1 2014, worth a combined $45.1M — up 1.1% from $44.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OCRX positions and 1 closed out — a net gain of 18 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $5.76M. The largest seller was Great Point Partners, cutting an estimated $3.09M.
- 36 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q1 2014, up from 18 in Q4 2013.
- Funds reported $45.1M of Ocera Therapeutics, Inc. stock for Q1 2014, up 1.1% quarter-over-quarter.
- 19 funds opened new Ocera Therapeutics, Inc. positions in Q1 2014 and 1 closed out, a net change of +18 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q1 2014 was Millennium Management, an estimated $5.76M added.
- The largest Ocera Therapeutics, Inc. seller in Q1 2014 was Great Point Partners, an estimated $3.09M sold.
Based on aggregated 13F filings for Q1 2014.